A study in asthma patients to evaluate efficacy, safety and tolerability of 14 days once daily inhaled Interferon beta-1a after the onset of symptoms of an upper respiratory tract infection

Trial Identifier: D6230C00001
Sponsor: AstraZeneca
NCTID:: NCT02491684
Start Date: July 2015
Primary Completion Date: November 2016
Study Completion Date: November 2016
Condition: Asthma

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Argentina Buenos Aires, Argentina, C1414AIF
Argentina CABA, Argentina, C1425BEN
Argentina Ciudad Autonomade Buenos Aires, Argentina, 1426
Argentina Nueve de julio, Argentina, B6500EZL
Argentina Quilmes, Argentina, B1878FNR
Australia Bedford Park, Australia, 5042
Australia New Lambton, Australia, 2310
Australia Westmead, Australia, 2145
Australia Woolloongabba, Australia, 4102
Colombia Bogotá, Colombia, 110311
Colombia Floridablanca, Colombia, 680006
France Dijon, France, 21079
France Lyon Cedex 04, France, 69317
France Marseille, France, 13015
France Montpellier Cedex 5, France, 34295
France Paris Cedex 18, France, 75877
France Pessac, France, 33604
South Korea Bucheon-si, South Korea, 14584
South Korea Jeonju-si, South Korea, 54907
South Korea Seoul, South Korea, 05505
South Korea Seoul, South Korea, 02559
South Korea Seoul, South Korea, 03080
Spain Barcelona, Spain, 08003
Spain Málaga, Spain, 29010
Spain Marbella (Málaga), Spain, 29603
Spain Sevilla, Spain, 41071
Spain Valencia, Spain, 46017
United Kingdom Blackpool, United Kingdom, FY4 3AD
United Kingdom Bradford, United Kingdom, BD9 6RJ
United Kingdom Lancaster, United Kingdom, LA1 4RP
United Kingdom Leeds, United Kingdom, LS9 7TF
United Kingdom Manchester, United Kingdom, M23 9QZ
United Kingdom Nottingham, United Kingdom, NG5 1PB
United Kingdom Southampton, United Kingdom, SO9 4XY